Itraconazole

Major

Itraconazole Brentuximab Vedotin Injection Adcetris Increased brentuximab vedotin exposure and an increased risk of brentuximab vedotin-related adverse effects Details Itraconazole Brexpiprazole Rexulti Increased brexpiprazole exposure Details Itraconazole Brigatinib Alunbrig Increased brigatinib exposure Details Itraconazole Budesonide Entocort Increased budesonide exposure and an increased risk of budesonide-related adverse effects Details Itraconazole Budesonide Nasal Spray Rhinocort Increased budesonide exposure and an increased risk of budesonide-related adverse effects Details Itraconazole Budesonide Oral Inhalation Pulmicort Increased budesonide exposure and an increased risk of budesonide-related adverse effects Details Itraconazole Busulfan Injection Busulfex Increased busulfan exposure and an increased risk of busulfan-related adverse effects Details Itraconazole Cabazitaxel Injection Jevtana Increased cabazitaxel exposure Details Itraconazole Cabozantinib Cabometyx Increased cabozantinib exposure Details Itraconazole Cabozantinib (Thyroid Cancer) Cabometyx Increased cabozantinib exposure Details Itraconazole Calcifediol Rayaldee Altered serum levels of calcifediol Details Itraconazole Capmatinib Tabrecta Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Chloroquine Aralen® Increased risk of QT-interval prolongation Details Itraconazole Ciclesonide Nasal Spray Omnaris Increased ciclesonide exposure and an increased risk of ciclesonide-related adverse effects Details Itraconazole Ciclesonide Oral Inhalation Alvesco Increased ciclesonide exposure and an increased risk of ciclesonide-related adverse effects Details Itraconazole Clindamycin Injection ANTIROBE Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Clindamycin Topical C/T/S® Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Clindamycin Vaginal Cleocin Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Cobimetinib Cotellic Increased cobimetinib exposure Details Itraconazole Cyclosporine Injection Atopica Increased cycloSPORINE exposure and risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Itraconazole Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure and risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Itraconazole Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Itraconazole Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Itraconazole Darolutamide Nubeqa Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Itraconazole Dasatinib Phyrago Increased dasatinib exposure and an increased risk of QT interval prolongation Details Itraconazole Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Itraconazole Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Itraconazole Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Itraconazole Dexamethasone Injection Decadron Reduced CYP3A substrate exposure and increased dexAMETHasone exposure Details Itraconazole Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced CYP3A substrate exposure and increased dexAMETHasone exposure Details Itraconazole Diazepam Nasal Spray Valtoco Increased diazePAM exposure and an increased risk of diazePAM-related adverse effects Details Itraconazole Diazepam Rectal Diastat Increased diazePAM exposure and an increased risk of diazePAM-related adverse effects Details Itraconazole Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin toxicity (nausea, vomiting, arrhythmias) Details Itraconazole Docetaxel Beizray Increased DOCEtaxel exposure Details Itraconazole Docetaxel Injection Beizray Increased DOCEtaxel exposure Details Itraconazole Dolasetron Anzemet An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Dolasetron Injection Anzemet An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Dolutegravir Juluca® (as a combination product containing dolutegravir, rilpivirine) Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Doravirine Pifeltro Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details